Related references
Note: Only part of the references are listed.Identification of two tofacitinib subpopulations with different relative risk versus TNF inhibitors: an analysis of the open label, randomised controlled study ORAL Surveillance
Lars Erik Kristensen et al.
ANNALS OF THE RHEUMATIC DISEASES (2023)
Oral Ritlecitinib and Brepocitinib for Moderate-to-Severe Ulcerative Colitis: Results From a Randomized, Phase 2b Study
William J. Sandborn et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2023)
Positioning Filgotinib in the Treatment Algorithm of Moderate to Severe Ulcerative Colitis
Ferdinando D'Amico et al.
JOURNAL OF CROHNS & COLITIS (2022)
DOP38 Upadacitinib Therapy Reduces Ulcerative Colitis Symptoms as Early as Day 1
S Vermeire et al.
Journal of Crohns & Colitis (2022)
Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis
Steven R. Ytterberg et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis
Juan S. Lasa et al.
LANCET GASTROENTEROLOGY & HEPATOLOGY (2022)
Filgotinib: A Clinical Pharmacology Review
Florence Namour et al.
CLINICAL PHARMACOKINETICS (2022)
Emerging therapies for ulcerative colitis
Jurij Hanzel et al.
EXPERT REVIEW OF CLINICAL IMMUNOLOGY (2022)
Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials
Silvio Danese et al.
LANCET (2022)
Efficacy and safety of filgotinib as induction and maintenance therapy for Japanese patients with moderately to severely active ulcerative colitis: a post-hoc analysis of the phase 2b/3 SELECTION trial
Toshifumi Hibi et al.
INTESTINAL RESEARCH (2022)
Efficacy and Safety of Ivarmacitinib in Patients With Moderate-to-Severe, Active, Ulcerative Colitis: A Phase II Study
Baili Chen et al.
GASTROENTEROLOGY (2022)
The future of drug development for inflammatory bowel disease: the need to ACT (advanced combination treatment)
Silvio Danese et al.
GUT (2022)
Is Selectivity the JAKpot Winner for Inflammatory Bowel Disease Treatment?
Ferdinando D'Amico et al.
GASTROENTEROLOGY (2022)
Safety and Efficacy of Filgotinib: Up to 4-year Results From an Open-label Extension Study of Phase II Rheumatoid Arthritis Programs
Arthur Kavanaugh et al.
JOURNAL OF RHEUMATOLOGY (2021)
JAK1 inhibition and inflammatory bowel disease
Clare Harris et al.
RHEUMATOLOGY (2021)
Efficacy and Safety of SHR0302, a Highly Selective Janus Kinase 1 Inhibitor, in Patients with Moderate to Severe Atopic Dermatitis: A Phase II Randomized Clinical Trial
Yan Zhao et al.
AMERICAN JOURNAL OF CLINICAL DERMATOLOGY (2021)
Current and future status of JAK inhibitors
Donal P McLornan et al.
LANCET (2021)
Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b/3 double-blind, randomised, placebo-controlled trial
Brian G. Feagan et al.
LANCET (2021)
The JAK/STAT signaling pathway: from bench to clinic
Xiaoyi Hu et al.
SIGNAL TRANSDUCTION AND TARGETED THERAPY (2021)
Postapproval Comparative Safety Study of Tofacitinib and Biological Disease-Modifying Antirheumatic Drugs: 5-Year Results from a United States-Based Rheumatoid Arthritis Registry
Joel M. Kremer et al.
ACR OPEN RHEUMATOLOGY (2021)
Adverse events of special interest in clinical trials of rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and psoriasis with 37 066 patient-years of tofacitinib exposure
Gerd R. Burmester et al.
RMD OPEN (2021)
Upadacitinib in adults with moderate to severe atopic dermatitis: 16-week results from a randomized, placebo-controlled trial
Emma Guttman-Yassky et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2020)
Clinical Pharmacokinetics of Upadacitinib: Review of Data Relevant to the Rheumatoid Arthritis Indication
Mohamed-Eslam F. Mohamed et al.
CLINICAL PHARMACOKINETICS (2020)
Efficacy and Safety of Upadacitinib in a Randomized Trial of Patients With Crohn's Disease
William J. Sandborn et al.
GASTROENTEROLOGY (2020)
Global burden of inflammatory bowel disease
Vipul Jairath et al.
LANCET GASTROENTEROLOGY & HEPATOLOGY (2020)
The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017
Sudabeh Alatab et al.
LANCET GASTROENTEROLOGY & HEPATOLOGY (2020)
Clinical Pharmacology of Janus Kinase Inhibitors in Inflammatory Bowel Disease
Pavine L. C. Lefevre et al.
JOURNAL OF CROHNS & COLITIS (2020)
JAK-STAT pathway targeting for the treatment of inflammatory bowel disease
Azucena Salas et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2020)
Tofacitinib for Acute Severe Colitis: When the going Gets Tough, the Tough Get Going
Ferdinando D'Amico et al.
JOURNAL OF CROHNS & COLITIS (2020)
JAK selectivity for inflammatory bowel disease treatment: does it clinically matter?
Silvio Danese et al.
GUT (2019)
Effect of Filgotinib vs Placebo on Clinical Response in Patients With Moderate to Severe Rheumatoid Arthritis Refractory to Disease-Modifying Antirheumatic Drug Therapy: The FINCH 2 Randomized Clinical Trial
Mark C. Genovese et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2019)
JAK-STAT Signaling: A Double-Edged Sword of Immune Regulation and Cancer Progression
Katie L. Owen et al.
CANCERS (2019)
Comparison of baricitinib, upadacitinib, and tofacitinib mediated regulation of cytokine signaling in human leukocyte subpopulations
Iain B. McInnes et al.
ARTHRITIS RESEARCH & THERAPY (2019)
Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active ankylosing spondylitis (TORTUGA): results from a randomised, placebo-controlled, phase 2 trial
Desiree van der Heijde et al.
LANCET (2018)
Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active psoriatic arthritis (EQUATOR): results from a randomised, placebo-controlled, phase 2 trial
Philip Mease et al.
LANCET (2018)
Filgotinib (GLPG0634/GS-6034), an oral selective JAK1 inhibitor, is effective as monotherapy in patients with active rheumatoid arthritis: results from a randomised, dose-finding study (DARWIN 2)
A. Kavanaugh et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
Filgotinib (GLPG0634/GS-6034), an oral JAK1 selective inhibitor, is effective in combination with methotrexate (MTX) in patients with active rheumatoid arthritis and insufficient response to MTX: results from a randomised, dose-finding study (DARWIN 1)
R. Westhovens et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
Next generation of small molecules in inflammatory bowel disease
Pablo Olivera et al.
GUT (2017)
Clinical remission in patients with moderate-to-severe Crohn's disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trial
Severine Vermeire et al.
LANCET (2017)
Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis
William J. Sandborn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
JAK inhibition using tofacitinib for inflammatory bowel disease treatment: a hub for multiple inflammatory cytokines
Silvio Danese et al.
AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY (2016)
Characterizing unmet medical need and the potential role of new biologic treatment options in patients with ulcerative colitis and Crohn's disease: a systematic review and clinician surveys
Jason P. Gordon et al.
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY (2015)
The molecular regulation of Janus kinase (JAK) activation
Jeffrey J. Babon et al.
BIOCHEMICAL JOURNAL (2014)
Cytokines in inflammatory bowel disease
Markus F. Neurath
NATURE REVIEWS IMMUNOLOGY (2014)
A reproducible grading scale for histological assessment of inflammation in ulcerative colitis
K Geboes et al.
GUT (2000)
Share Paper
